Dendritic cell-based immunotherapy

被引：630
|
作者：
Sabado, Rachel L. [1 ]
Balan, Sreekumar [1 ]
Bhardwaj, Nina [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
来源：
CELL RESEARCH | 2017年 / 27卷 / 01期
关键词：
dendritic cell; immunotherapy; CERVICAL-CANCER PATIENTS; REGULATORY T-CELLS; INTEGRATED IMMUNE-RESPONSE; LONG PEPTIDE VACCINE; MELANOMA PATIENTS; IN-VIVO; SIPULEUCEL-T; LYMPH-NODES; LISTERIA-MONOCYTOGENES; ANTITUMOR IMMUNITY;
D O I：
10.1038/cr.2016.157
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.
引用
收藏
页码：74 / 95
页数：22
相关论文
共 50 条
  • [41] NK cell-based immunotherapy: new prospects and involvement of dendritic cells
    Borg, C
    Taieb, J
    Terme, M
    Maruyama, K
    Flament, C
    Angevin, E
    Zitvogel, L
    BULLETIN DU CANCER, 2003, 90 (8-9) : 699 - 705
  • [42] Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme
    Yang, Liu
    Guo, Geng
    Niu, Xiao-yuan
    Liu, Jing
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [43] Breaking tolerance to tumors with dendritic cell-based immunotherapy
    Mende, I
    Engleman, EG
    THERAPEUTIC OLIGONUCLEOTIDES: TRANSCRIPTIONAL AND TRANSLATIONAL STRATEGIES FOR SILENCING GENE EXPRESSION, 2005, 1058 : 96 - 104
  • [44] Recent clinical development of dendritic cell-based immunotherapy for prostate cancer
    Rini, B
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (11) : 1729 - 1734
  • [45] Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
    Van Lint, Sandra
    Wilgenhof, Sofie
    Heirman, Carlo
    Corthals, Jurgen
    Breckpot, Karine
    Bonehill, Aude
    Neyns, Bart
    Thielemans, Kris
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (09) : 959 - 967
  • [46] Dendritic Cell-based Immunotherapy for Rheumatoid Arthritis: from Bench to Bedside
    Ahmed, Md. Selim
    Bae, Yong-Soo
    IMMUNE NETWORK, 2016, 16 (01) : 44 - 51
  • [47] Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy
    Reis, Edione C.
    da Silva, Lais T.
    da Silva, Wanessa C.
    Rios, Alexandre
    Duarte, Alberto J.
    Oshiro, Telma M.
    Crovella, Sergio
    Pontillo, Alessandra
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1995 - 2002
  • [48] Principles of dendritic cell-based immunotherapy in myeloid leukemia
    Westers, Theresia M.
    Houtenbos, Ilse
    van de Loosdrecht, Arjan A.
    Ossenkoppele, Gert J.
    IMMUNOBIOLOGY, 2006, 211 (6-8) : 663 - 676
  • [49] Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
    Van Acker, Heleen H.
    Versteven, Maarten
    Lichtenegger, Felix S.
    Roex, Gils
    Campillo-Davo, Diana
    Lion, Eva
    Subklewe, Marion
    Van Tendeloo, Viggo F.
    Berneman, Zwi N.
    Anguille, Sebastien
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (05)
  • [50] Dendritic cell-based cancer immunotherapy for colorectal cancer
    Mikio Kajihara
    Kazuki Takakura
    Tomoya Kanai
    Zensho Ito
    Keisuke Saito
    Shinichiro Takami
    Shigetaka Shimodaira
    Masato Okamoto
    Toshifumi Ohkusa
    Shigeo Koido
    World Journal of Gastroenterology, 2016, (17) : 4275 - 4286
12345